TRAIL, Fas Ligand, TNF and TLR3 in Cancer

1. Front Matter

   Pages i-xiii

   PDF

2. Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

   • Jessica Wagner, Christina Leah Kline, Wafik El-Deiry

   Pages 1-25

3. TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer

   • Lubna Danish, Daniela Stöhr, Peter Scheurich, Nadine Pollak

   Pages 27-57

4. IAPs and Resistance to Death Receptors in Cancer

   • Laurence Dubrez, Simone Fulda

   Pages 59-77

5. Bcl-2 Proteins and TRAIL Resistance in Melanoma

   • Jürgen Eberle

   Pages 79-90

6. Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4

   • James Sledziona, Vivek M. Rangnekar

   Pages 91-106

7. Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy

   • Andrea Mohr, Ralf Zwacka

   Pages 107-129

8. Atypical Immune Functions of CD95/CD95L

   • Amanda Poissonnier, Patrick Legembre

   Pages 131-157

9. TLR3 Is a Death Receptor Target in Cancer Therapy

   • Yann Estornes, Toufic Renno, Serge Lebecque

   Pages 159-185

10. Fas/CD95, Lipid Rafts, and Cancer

    • Faustino Mollinedo, Consuelo Gajate

    Pages 187-227

11. Role of Sphingolipids in Death Receptor Signalling

    • Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher et al.

    Pages 229-245

12. Posttranslational Modifications and Death Receptor Signalling

    • Olivier Micheau

    Pages 247-290

13. System Modeling of Receptor-Induced Apoptosis

    • François Bertaux, Dirk Drasdo, Grégory Batt

    Pages 291-307

14. Back Matter

    Pages 309-317

    PDF

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

• TRAIL
• Fas Ligand
• TRAIL-R1
• TRAIL-R2
• TNF-RI

• INSERM, LNC UMR 1231, Dijon, France

  Olivier Micheau

Dr. Olivier Micheau is a research director of the INSERM (French National Institute of Health), UMR1231. He received his PhD in  Biochemistry and Molecular and Cellular Biology in 1999 from the University of Burgundy, France. He next moved as a post-doctoral fellow in Jurg Tschopp’s laboratory in Epalinges, Switzerland, from 1999 to 2003, where he elucidated the molecular mechanisms underlying TNFR1’s dual signaling ability. He described for the first time TNFR1 cytosolic pro-apoptotic complex II. In 2003 he joined the INSERM unit U517 headed by Professor E. Solary in Dijon, France, as an INSERM researcher. Member of several scientific councils, including INSERM CSS3 (2012-2016) and Fondation ARC pour la recherche sur le cancer, a French Charity (since 2015), he is also Associate Editor of the British Journal of Pharmacology since 2012. His scientific interest focuses on TRAIL receptor signaling and its use in cancer therapy.

Policies and ethics